Skip to Content
  • Previous Rank
  • Revenues ($M)
  • Revenue Percent Change
  • Profits ($M)
  • Profits Percent Change
  • Assets ($M)
  • Employees

AbbVie—a North Chicago, Ill.-based biopharmaceutical company—is laying the foundation for its future as the company looks to move beyond its flagship drug Humira. Global Humira sales dropped 5.6% to $4.4 billion in the first quarter of 2019. The drug took a steep 27.9% downturn in international markets during the same time period in part due to the entry of biosimilars in Europe. This contrasts with global Humira sales in FY2018, which increased 8.2% year-over-year to $19.9 billion. Still, AbbVie raised its earnings-per-share guidance for 2019 in April coming off the FDA approval of its drug Skyrizi. The plaque psoriasis drug has been reported to be set to launch later this year.

Company Info

Richard A. Gonzalez
CEO Title
Chairman & Chief Executive Officer
Health Care
HQ Location
North Chicago, Ill.
Years on Fortune 500 List6
Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Purchase Now

AbbVie Rank History


Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$32,753.016.1%
Profits ($M)$5,687.07.1%
Assets ($M)$59,352.0-
Total Stockholder Equity ($M)$-8,446.0-

Profit Ratios

Profit as % of Revenues17.4%
Profits as % of Assets9.6%
Profits as % of Stockholder Equity-

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)3.66
EPS % Change (from 2017)10.9%
EPS % Change (5 year annual rate)7.4%
EPS % Change (10 year annual rate)-

Total Return

Total Return to Investors (2018)-1.2%
Total Return to Investors (5 year, annualized)15.7%
Total Return to Investors (10 year, annualized)-